Latest news with #Intensity
Yahoo
12-06-2025
- Business
- Yahoo
Intensity Therapeutics, Inc. Announces Pricing of Public Offering
SHELTON, Conn., June 11, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced the pricing of its underwritten public offering of 6,675,000 shares of its common stock at a public offering price of $0.30 per share, for gross proceeds of $2,002,500, before deducting underwriting discounts, commissions and offering expenses. All of the shares of common stock are being offered by the Company. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 1,001,250 shares of common stock at the public offering price less discounts and commissions, to cover over-allotments. The offering is expected to close on June 13, 2025, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering for the enrollment of patients and to reach data read out in the INVINCIBLE-4 Study, for the treatment of existing patients enrolled in the INVINCIBLE-3 Study, and for working capital and general corporate purposes. ThinkEquity is acting as sole book-running manager for the offering. The securities will be offered and sold pursuant to a shelf registration statement on Form S-3 (File No. 333-280681), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the "SEC") on July 3, 2024 and declared effective on July 11, 2024. The offering will be made only by means of a written prospectus and related prospectus supplement. A prospectus supplement and accompanying prospectus describing the terms of the offering will be filed with the SEC on its website at Copies of the prospectus supplement and the accompanying prospectus relating to the offering may also be obtained, when available, from the offices of ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Intensity Therapeutics, Inc:Intensity is a late-stage clinical biotechnology company whose novel engineered chemistry enables aqueous cytotoxic-containing drug formulations to mix and saturate a tumor's dense, high-fat, pressurized environment following direct intratumoral injection. As a result of the saturation, Intensity's clinical trials have demonstrated the ability of the investigational new drug, INT230-6, to kill tumors and elicit an adaptive immune response within days of injection, representing a new approach to cancer cell death that holds the potential to shift the treatment paradigm and turn many deadly cancers into chronic diseases even for malignancies that do not respond to conventional immunotherapy. Intensity has completed two clinical studies and enrolled over 200 patients using INT230-6: a Phase 1/2 dose escalation study in metastatic cancers including sarcomas (NCT03058289), and a Phase 2 randomized control clinical trial in locally advanced breast cancer (the "INVINCIBLE-2 Study") (NCT04781725) in women without undergoing chemotherapy prior to their surgery. The Company initiated a Phase 3 trial in soft tissue sarcoma (the "INVINCIBLE-3 Study") (NCT06263231), testing INT230-6 as second or third-line monotherapy compared to the standard of care ("SOC") with overall survival as an endpoint. Intensity also initiated a Phase 2 study in collaboration with The Swiss Group for Clinical Cancer Research, SAKK (the "INVINCIBLE-4 Study") (NCT06358573) as part of a Phase 2/3 program evaluating INT230-6 followed by the SOC immunochemotherapy and the SOC alone for patients with presurgical triple-negative breast cancer. Pathological complete response ("pCR") is the endpoint. For more information about Intensity, including publications, papers, and posters about its novel approach to cancer therapeutics, visit Forward-Looking Statements:Certain statements in this press release may constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date. These statements include, but are not limited to, statements relating to the completion of the public offering on the anticipated terms or at all, the Company's intended use of proceeds from the offering, the Company's expected future plans, cash runway, development activities, projected milestones, business activities or results. When or if used in this communication, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to the Company or its management, may identify forward-looking statements. The forward-looking statements contained in this press release are based on management's current expectations and projections about future events. Nevertheless, actual results or events could differ materially from the plans, intentions, and expectations disclosed in, or implied by, the forward-looking statements. These risks and uncertainties, many of which are beyond our control, include: the initiation, timing, progress and results of future preclinical studies and clinical trials and research and development programs; the need to raise additional funding before the Company can expect to generate any revenues from product sales; plans to develop and commercialize product candidates; the timing or likelihood of regulatory filings and approvals; the ability of the Company's research to generate and advance additional product candidates; the implementation of the Company's business model, strategic plans for the Company's business, product candidates and technology; commercialization, marketing and manufacturing capabilities and strategy; the rate and degree of market acceptance and clinical utility of the Company's system; the Company's competitive position; the Company's intellectual property position; developments and projections relating to the Company's competitors and its industry; the Company's ability to maintain and establish collaborations or obtain additional funding; expectations related to the use of cash and cash equivalents and investments; estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company may not satisfy the Nasdaq Capital Market's requirements for continued listing and be subject to delisting; and other risks described in the section entitled "Risk Factors" in the Company's preliminary prospectus supplement filed with the SEC, the Company's Annual Report on Form 10-K for the year ended December 31, 2024 and in the Company's subsequent SEC filings, which can be obtained on the SEC website at Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations, and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law. For Investor Relations Inquiries: Investor Relations Contact:Justin KulikJustin@ IR(516) 222-2560 Media Contact:Jules AbrahamCORE IRpr@ View original content to download multimedia: SOURCE Intensity Therapeutics Inc.
Yahoo
11-06-2025
- Business
- Yahoo
Intensity Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
SHELTON, Conn., June 11, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced that it intends to offer to sell shares of its common stock in an underwritten public offering. All of the shares of common stock are to be sold by the Company. ThinkEquity is acting as sole book-running manager for the offering. The Company intends to use the net proceeds from the offering for the enrollment of patients and to reach data read out in the INVINCIBLE-4 Study, for the treatment of existing patients enrolled in the INVINCIBLE-3 Study, and for working capital and general corporate purposes. The securities will be offered and sold pursuant to a shelf registration statement on Form S-3 (File No. 333-280681), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the "SEC") on July 3, 2024 and declared effective on July 11, 2024. The offering will be made only by means of a written prospectus and related prospectus supplement. A preliminary prospectus supplement and accompanying prospectus describing the terms of the offering has been or will be filed with the SEC on its website at Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering may also be obtained from the offices of ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004. Before investing in this offering, interested parties should read in their entirety the preliminary prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such preliminary prospectus supplement and the accompanying prospectus, which provide more information about the Company and such offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. About Intensity Therapeutics, Inc: Intensity is a late-stage clinical biotechnology company whose novel engineered chemistry enables aqueous cytotoxic-containing drug formulations to mix and saturate a tumor's dense, high-fat, pressurized environment following direct intratumoral injection. As a result of the saturation, Intensity's clinical trials have demonstrated the ability of the investigational new drug, INT230-6, to kill tumors and elicit an adaptive immune response within days of injection, representing a new approach to cancer cell death that holds the potential to shift the treatment paradigm and turn many deadly cancers into chronic diseases even for malignancies that do not respond to conventional immunotherapy. Intensity has completed two clinical studies and enrolled over 200 patients using INT230-6: a Phase 1/2 dose escalation study in metastatic cancers including sarcomas (NCT03058289), and a Phase 2 randomized control clinical trial in locally advanced breast cancer (the "INVINCIBLE-2 Study") (NCT04781725) in women without undergoing chemotherapy prior to their surgery. The Company initiated a Phase 3 trial in soft tissue sarcoma (the "INVINCIBLE-3 Study") (NCT06263231), testing INT230-6 as second or third-line monotherapy compared to the standard of care ("SOC") with overall survival as an endpoint. Intensity also initiated a Phase 2 study in collaboration with The Swiss Group for Clinical Cancer Research, SAKK (the "INVINCIBLE-4 Study") (NCT06358573) as part of a Phase 2/3 program evaluating INT230-6 followed by the SOC immunochemotherapy and the SOC alone for patients with presurgical triple-negative breast cancer. Pathological complete response ("pCR") is the endpoint. For more information about Intensity, including publications, papers, and posters about its novel approach to cancer therapeutics, visit Forward-Looking Statements Certain statements in this press release may constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date. These statements include, but are not limited to, statements relating to the completion of the public offering on the anticipated terms or at all, the Company's intended use of proceeds from the offering, the Company's expected future plans, cash runway, development activities, projected milestones, business activities or results. When or if used in this communication, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to the Company or its management, may identify forward-looking statements. The forward-looking statements contained in this press release are based on management's current expectations and projections about future events. Nevertheless, actual results or events could differ materially from the plans, intentions, and expectations disclosed in, or implied by, the forward-looking statements. These risks and uncertainties, many of which are beyond our control, include: the initiation, timing, progress and results of future preclinical studies and clinical trials and research and development programs; the need to raise additional funding before the Company can expect to generate any revenues from product sales; plans to develop and commercialize product candidates; the timing or likelihood of regulatory filings and approvals; the ability of the Company's research to generate and advance additional product candidates; the implementation of the Company's business model, strategic plans for the Company's business, product candidates and technology; commercialization, marketing and manufacturing capabilities and strategy; the rate and degree of market acceptance and clinical utility of the Company's system; the Company's competitive position; the Company's intellectual property position; developments and projections relating to the Company's competitors and its industry; the Company's ability to maintain and establish collaborations or obtain additional funding; expectations related to the use of cash and cash equivalents and investments; estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company may not satisfy the Nasdaq Capital Market's requirements for continued listing and be subject to delisting; and other risks described in the section entitled "Risk Factors" in the Company's preliminary prospectus supplement to be filed with the SEC, the Company's Annual Report on Form 10-K for the year ended December 31, 2024 and in the Company's subsequent SEC filings, which can be obtained on the SEC website at Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations, and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law. For Investor Relations Inquiries: Investor Relations Contact:Justin KulikJustin@ IR(516) 222-2560 Media Contact:Jules AbrahamCORE IRpr@ View original content to download multimedia: SOURCE Intensity Therapeutics Inc.
Yahoo
10-06-2025
- Sport
- Yahoo
The Jurgen Klopp disciple ready to boost Pep Guardiola's Man City
Some worrying news for bookshops on Merseyside. Any copies of Intensity by Pep Lijnders are likely to remain on the shelves. They may want to instead store them with El Nino, the Fernando Torres autobiography that was a love story to Liverpool. But Torres joined Chelsea and now, barely a year after leaving Liverpool, Lijnders' return to English football comes alongside Pep Guardiola. Advertisement The supporters who branded Trent Alexander-Arnold a traitor for heading for Real Madrid – though one of their complaints has been removed now he is no longer going on a free transfer, but for €10m – may transfer their irritation to Jurgen Klopp's former sidekick after his move to Manchester City was confirmed ahead of the Club World Cup, with every game live on DAZN. City, of course, is the club that ensured one of the great Liverpool managers won just one league title. If a year away has illustrated the legacy Klopp and Lijnders left, with Arne Slot's success reflecting well on the previous regime, it may have been chastening in other respects. Klopp's popularity in Germany has been dented by the decision of a man who was a byword for authenticity to work for the despised Red Bull group. Lijnders, once touted as a potential successor to Klopp at Anfield, floundered in his second attempt to go it alone. He was sacked by RB Salzburg – a couple of weeks before Klopp took up his role at their parent organisation – with the usually dominant force in Austrian football only fifth in the Bundesliga, 10 points off the lead, and having lost five of their six Champions League games. Defeats without scoring to Sparta Prague, Brest and Dinamo Zagreb were scarcely the great European nights Lijnders experienced at Liverpool. Take out the tribalism of football, however, and there is logic on both his and Guardiola's side; this could be a marriage of considerable convenience. City have parted company with three assistant coaches, in Carlos Vicens, Inigo Domingues and Juanma Lillo, which could leave Guardiola looking lonely. Lillo, in particular, was a symbolic figure; Guardiola admired him so much that he went to Mexico to end his playing career under Lillo at Dorados Sinaloa. Advertisement Yet if City's explanation was simply that Lillo, whose contract expired this summer, wanted to return to Spain – and he never spoke much English – Guardiola's most torrid season featured many a strange decision. The Guardiola-Lillo axis may not have worked as well as it did. At 42, Lijnders is 17 years younger than the wizened Spaniard, with a Premier League pedigree, multilingual skills – speaking Spanish and Portuguese – and bringing an energy Klopp appreciated as he aged. That City struggled with the physicality of many an opponent last season could give an added reason to appoint a coach responsible for some Liverpool sides who were primed to outrun anyone. Lijnders and Jurgen Klopp pose with the FA Cup and the Carabao Cup during the Liverpool trophy parade in May 2022 (Getty) For Lijnders, meanwhile, a step backwards could nevertheless bring one of the plum coaching jobs, just not a managerial post. He was interviewed by Norwich, before they appointed Liam Manning. The City Football Group, with their portfolio of clubs, could suit Lijnders' long-term plan to get back into management. With Klopp yet to return to management, he has now found a new patron. A double act of Pep and Pep may sound good too. A theme of Guardiola's career has been his ability to win with different assistants, starting with Tito Vilanova at Barcelona. At City, he has been joined by Mikel Arteta, Brian Kidd, Domenec Torrent, Rodolfo Borrell, Enzo Maresca and Lillo. Advertisement Lijnders' partnership with Klopp followed the break-up of his long-term alliance with Zeljko Buvac. The Dutchman's ideas nevertheless took Liverpool to greater heights; arguably they played less heavy-metal football but they won the 2019 Champions League and the 2020 Premier League and pursued the quadruple in 2022. Lijnders during his time at FC Salzburg (Getty Images) His brief spell at Salzburg, like a similarly short stint at Nijmegen in 2018, could suggest that Lijnders is no manager. While he could coin Klopp-style soundbites – 'our identity is intensity' was one – perhaps they didn't sound right without Klopp and he lacked his mentor's degree in people. Lijnders is thought to be aware of his shortcomings. As a coach, though, his reputation is safe. Klopp initially inherited him, asked by Fenway Sports Group's Mike Gordon to give him a go. He agreed, ringing the FSG president a few weeks into his reign to tell him that he didn't like Lijnders... he loved him. He brought him back to Anfield after Buvac left. Pep Guardiola with his Manchester City assistant Juanma Lillo at the Tottenham Hotspur Stadium in February (Getty) He played him at the racket sport padel, often losing to a man 16 years his junior; that was a sign of Lijnders' competitiveness. Unlike Peter Krawietz, Klopp's other assistant and a far quieter figure, Lijnders had a profile in his own right. He did the pre-match media duties before Carabao Cup games, to prepare him for the return to management, which then backfired. Advertisement Instead, he has now joined a select group who have crossed the great divide and played a part for arguably the two most influential managers of their generation. For Ilkay Gundogan, Robert Lewandowski and Thiago Alcantara it was as players. For Lijnders, in the opposing dugout for titanic duels as Klopp enjoyed a rare winning record against Guardiola, it is as a coach. Liverpool could win the games but, over 38 matches, it was City who won the titles in Lijnders' last four seasons at Anfield. He couldn't beat Guardiola, so he has now joined him. You can sign up to DAZN to watch every Club World Cup game for free
Irish Independent
10-06-2025
- Sport
- Irish Independent
The Jurgen Klopp disciple ready to boost Pep Guardiola's Manchester City
Some worrying news for bookshops on Merseyside. Any copies of Intensity by Pep Lijnders are likely to remain on the shelves. They may want to instead store them with El Nino, the Fernando Torres autobiography that was a love story to Liverpool. But Torres joined Chelsea and now, barely a year after leaving Liverpool, Lijnders' return to English football comes alongside Pep Guardiola.
The Independent
03-06-2025
- Business
- The Independent
The Jurgen Klopp disciple ready to boost Pep Guardiola's Man City
Some worrying news for bookshops on Merseyside. Any copies of 'Intensity' by Pep Lijnders are likely to remain unsold on the shelves. They may want to instead store them with 'El Nino', the Fernando Torres autobiography that was a love story to Liverpool. But Torres joined Chelsea and now, barely a year after leaving Liverpool, Lijnders' return to English football could come by Pep Guardiola 's side. The supporters who branded Trent Alexander-Arnold a traitor for heading for Real Madrid – though one of their complaints has been removed now he is no longer going on a free transfer, but for €10m – may transfer their irritation to Jurgen Klopp 's sidekick should he materialise at Manchester City, the club who ensured one of the great Liverpool managers won a lone league title. If a year away has illustrated the legacy Klopp and Lijnders left, with Arne Slot's success reflecting well on the previous regime, it may have been chastening in other respects. Klopp's popularity in Germany has been dented by the decision of a man who was a byword for authenticity to work for the despised Red Bull group. Lijnders, once touted as a potential successor to Klopp at Anfield, floundered in his second attempt to go it alone. He was sacked by RB Salzburg – a couple of weeks before Klopp took up his role at their parent organisation – with the usually dominant force in Austrian football only fifth in the Bundesliga, 10 points off the lead, and having lost five of their six Champions League games. Defeats without scoring to Sparta Prague, Brest and Dinamo Zagreb were scarcely the great European nights Lijnders experienced at Liverpool. Take out the tribalism of football, however, and there is logic on both his and Guardiola's side; this could be a marriage of considerable convenience. City parted company with three assistant coaches, in Carlos Vicens, Inigo Domingues and Juanma Lillo, which could leave Guardiola looking lonely. Lillo, in particular, was a symbolic figure; Guardiola admired him so much he went to Mexico to end his playing career under Lillo at Dorados Sinaloa. Yet if City's explanation was simply that Lillo, whose contract expired this summer, wanted to return to Spain – and he never spoke much English – Guardiola's most torrid season featured many a strange decision. The Guardiola-Lillo axis may not have worked as well as it did. At 42, Lijnders is 17 years younger than the wizened Spaniard, with a Premier League pedigree, multilingual – speaking Spanish and Portuguese – and bringing an energy Klopp appreciated as he aged. That City struggled with the physicality of many an opponent last season could give an added reason to appoint a coach responsible for some Liverpool sides who were primed to outrun anyone. For Lijnders, meanwhile, a step backwards could nevertheless bring one of the plum coaching jobs, just not a managerial post. He was interviewed by Norwich, before they appointed Liam Manning. The City Football Group, with their portfolio of clubs, could suit Lijnders' long-term plan to get back into management. Or, if Klopp does not return to management, he could do with finding a new patron. A double act of Pep and Pep may sound good. A theme of Guardiola's career has been his ability to win with different assistants, starting with Tito Vilanova at Barcelona. At City, he has been joined by Mikel Arteta, Brian Kidd, Domenec Torrent, Rodolfo Borrell, Enzo Maresca and Lillo. Lijnders' partnership with Klopp followed the break-up of his long-term alliance with Zeljko Buvac. The Dutchman's ideas nevertheless took Liverpool to greater heights; arguably they played less heavy-metal football but they won the 2019 Champions League and the 2020 Premier League and pursued the quadruple in 2022. His brief spell at Salzburg, like a similarly short stint at Nijmegen in 2018, could suggest that Lijnders is no manager. While he could coin Klopp-style soundbites – 'our identity is intensity' was one – perhaps they didn't sound right without Klopp and he lacked his mentor's degree in people. Lijnders is thought to be aware of his shortcomings. As a coach, though, his reputation is safe. Klopp initially inherited him, asked by Fenway Sports Group's Mike Gordon to give him a go. He agreed, ringing the FSG president a few weeks into his reign to tell him that he didn't like Lijnders only, after a dramatic pause, to add that he loved him. He brought him back to Anfield after Buvac left. He played him at padel, often losing to a man 16 years his junior; that was a sign of Lijnders' competitiveness. Unlike Peter Krawietz, Klopp's other assistant and a far quieter figure, Lijnders had a profile in his own right. He did the pre-match media duties before Carabao Cup games, to prepare him for the return to management, which then backfired. Instead, he is primed to join the select group who have crossed the great divide and played a part for arguably the two most influential managers of their generation. For Ilkay Gundogan, Robert Lewandowski and Thiago Alcantara, however, it was as players. For Lijnders, in the opposing dugout for titanic duels as Klopp enjoyed a rare winning record against Guardiola, it will be as a coach. Liverpool could win the games but, over 38 matches, City won the title in Lijnders' last four seasons at Anfield. So if he couldn't beat Guardiola, he will now join him.
